Revenue - For the three months ended September 30, 2021, revenue was approximately $29,000, an increase of $1,000 compared to approximately $28,000 for the same period in 2020[159]. - For the nine months ended September 30, 2021, revenue was approximately $0.3 million, a decrease of $0.7 million compared to approximately $1.0 million for the same period in 2020[167]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2021, were approximately $9.4 million, an increase of $6.9 million from $2.5 million for the same period in 2020[161]. - Research and development expenses for the nine months ended September 30, 2021, were approximately $20.8 million, an increase of $12.6 million from $8.2 million for the same period in 2020[168]. - The company anticipates research and development expenses to increase for the remainder of 2021[162]. General and Administrative Expenses - General and administrative expenses for the three months ended September 30, 2021, were approximately $1.9 million, a decrease of $0.5 million from $2.4 million for the same period in 2020[164]. - General and administrative expenses for the nine months ended September 30, 2021, were approximately $6.4 million, an increase of $0.6 million from $5.8 million for the same period in 2020[169]. Operating Losses and Deficit - As of September 30, 2021, the accumulated deficit was $170.1 million, with expectations of continued significant operating losses[170]. Cash Flow - Net cash used in operating activities was approximately $16.8 million for the nine months ended September 30, 2021, compared to approximately $11.6 million for the same period in 2020[173]. - Net cash provided by financing activities was $36.3 million for the nine months ended September 30, 2021, compared to $27.6 million for the same period in 2020[176].
Checkpoint Therapeutics(CKPT) - 2021 Q3 - Quarterly Report